Drug intelligence / Profile preview

afatinib + sirolimus

Development stage: Discontinued
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: Oral

Overview

A combination of afatinib, an irreversible ErbB family blocker that covalently binds to the kinase domains of epidermal growth factor receptor (EGFR) and human EGFRs (HER), and sirolimus, an mTOR inhibitor. This combination was investigated in a phase Ib clinical trial for patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) and/or disease progression following prior erlotinib/gefitinib treatment. It was studied as a potential approach to reverse acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs).

Targets

RNR (Ribonucleotide reductase)FKBP1AERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)Mechanistic target of rapamycin complex 1EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on afatinib + sirolimus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on afatinib + sirolimus.

Explore the full profile